Home
IMPORTANT INFORMATION
31 August 2016

www.scripclinicalresearch.com is now an archive site and will not be updated with new content.
Scrip will continue to cover the business of outsourced clinical trials through Scrip Intelligence www.scripintelligence.com

 
21 November 2012
Medpace has acquired MediTech Strategic Consultants (MediTech), a European CRO dedicated to medical device clinical trials and services related to development and commercialization of medical devices. MediTech joins Medpace as a strategic European acquisition, expanding Medpace's European device ...
21 November 2012
The decks have been cleared for establishing a new autonomous body in Pakistan to regulate the manufacture and sale of drugs, medical devices and other therapeutic products. The bill for establishing the Drug Regulatory Authority of Pakistan (DRAP) was signed into law on 12 November and its ...
19 November 2012
Janssen Research & Development (Janssen R&D), with early commitments from Merck & Co and Eli Lilly, has established a global Investigator Databank designed to improve the efficiency of industry-sponsored drug studies by reducing the burden on clinical investigators who may grow weary of ...
15 November 2012
The law in the UK on what constitutes an exception to patent infringement in clinical/field trials involving 'on-patent' drugs (innovative drugs which are protected by patents held by third parties) is uncertain and less generous than in other European member states or the US. This has led to ...
 
21 November 2012
Medpace has acquired MediTech Strategic Consultants (MediTech), a European CRO dedicated to medical device clinical trials and services related to development and commercialization of medical devices. MediTech joins Medpace as a strategic European acquisition, expanding Medpace's European device ...
21 November 2012
The decks have been cleared for establishing a new autonomous body in Pakistan to regulate the manufacture and sale of drugs, medical devices and other therapeutic products. The bill for establishing the Drug Regulatory Authority of Pakistan (DRAP) was signed into law on 12 November and its ...
19 November 2012
Janssen Research & Development (Janssen R&D), with early commitments from Merck & Co and Eli Lilly, has established a global Investigator Databank designed to improve the efficiency of industry-sponsored drug studies by reducing the burden on clinical investigators who may grow weary of ...
15 November 2012
The law in the UK on what constitutes an exception to patent infringement in clinical/field trials involving 'on-patent' drugs (innovative drugs which are protected by patents held by third parties) is uncertain and less generous than in other European member states or the US. This has led to ...
07 November 2012
Parexel has reported financial results in line with analysis predictions and a penny shy of the consensus for the first quarter of Fiscal Year 2013. For the three months ended September 30, 2012 service revenue has increased by 25.4% to $394.8 million compared with $314.7 million in the prior year ...
 
12 November 2012
Glenn Bilawsky is Precision Health Economics' new CEO. Bilawsky served as CEO of the i3 division of UnitedHealth Group for more than eight years, and he brings more than 25 years of pharmaceutical and contract research experience and has been instrumental in helping several organisations achieve ...
12 November 2012
Among her many other official duties, Her Royal Highness, Camilla the Duchess of Cornwall is President of the UK National Osteoporosis Society. Camilla’s mother died as a result of osteoporosis in 1994 and, in fact, hip fractures (which can be linked to osteoporosis) are reported to cause more than ...
07 November 2012
Experts from a variety of biotech fields, including research, investment, development and supply, sat down in London to discuss the challenges associated with clinical supply chain management in the industry, Mike Ward moderated the discussion. Participants: Ken Getz, Tuft's Center for the Study ...
02 November 2012
As many as 30% of subjects taking part in Phase III clinical studies drop out. Grueling schedules, high travel costs and the time taken to be reimbursed for expenses are all factors in these high drop-out rates and this can cause a trial to be delayed or even cancelled. It is crucial to keep ...
 
Jonathan Fishbein named as RPS CMO ReSearch Pharmaceutical Services (RPS), has appointed Dr Jonathan Fishbein as executive vice-president and chief medical officer. Dr Fishbein joins RPS having recently served as a Vice President in several medical and scientific capacities at ICON Clinical Research . Dr Fishbein has over 20 years ... Phlexglobal hires new CTO Phlexglobal has appointed a new chief technology officer to reaffirm the company as Trial Master Files experts. Peter McNaney , formerly of Clinical Solutions, will manage large scale technology and service transformations and product development at Phlexglobal. Chiltern promotes Aize Smink and Linda Christmas Chiltern has promoted Aize Smink and Linda Christmas, formally vice-president of global clinical development and senior executive, global resourcing solutions respectively. Smink will now be chief operating officer. In this new position, he will provide leadership and oversight of Chiltern’s ...
 
Over the past 18 months the market has witnessed a series of transactions involving the sale of pharmaceutical consulting firms. Recent deal activity includes the acquisitions of Bridgehead International, Double Helix Development, and the Drug Safety Alliance with buyers spanning other consulting ...
From clinician notes to insurance claims and laboratory test results to adverse event reports, health care systems are awash with data and data volumes are growing rapidly. According to a recent Oracle survey, U.S. and Canadian healthcare organisation are accumulating 85% more data than two years ...
From study recruitment, through to patient testing and specimen collection, the desire for increased patient centricity in clinical trials is shaking up the clinical trial supply chain. The potential for a sea change in how and where clinical trials are conducted is presenting opportunities for new ...
Companies that provide technology-enabled solutions that improve the quality and efficiency of clinical trials could soon find themselves attractive partners or acquisition targets for new entrants to the healthcare space. The potential to leverage clinical trial technologies such as ePRO to ...
Research sites behave as though they ‘own’ patients, but of course they don’t, they are only gate keepers. Patients are fully in charge of their own medical care and are the final arbiters of whether they would like to participate in a clinical trial or not. It would make sense then, to assume that ...
There has been increased interest across the life sciences industry to use lower-cost regions such as India, China, Eastern Europe, South America and South Africa to support functions including data management, programming, statistics, pharmacovigilance and medical writing across drug development ...
 
 

 
EVENTS
 
Expecting data for this section.
© 2016 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
 

In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer.

By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way Scrip Clinical Research uses cookies please go to our Cookie Policy page.